Is Lilly's Dividend Safe?



Eli Lilly (NYSE: LLY) is one of the globe's biggest drug companies. It's a major player in providing diabetes treatments and is often included in dividend investor's portfolios. Big drug companies ...

Eli Lilly (NYSE: LLY) is one of the globe's biggest drug companies. It's a major player in providing diabetes treatments and is often included in dividend investor's portfolios. Big drug companies such as Eli Lilly, Novo Nordisk (NYSE: NVO), and AstraZeneca (NYSE: AZN) offer investors predictable dividend-friendly revenue regardless of the economy's whims and whispers. But investors are correct to wonder if Lilly's dividend can be sustained in light of billions in at-risk revenue tied to patent expiration on two of the company's top selling drugs. In the following slideshow you'll see whether I think Lilly's dividend is safe and gain insight into how Lilly's dividend payout matches up with industry peers Novo Nordisk and AstraZeneca.



Total Views
Views on SlideShare
Embed Views



10 Embeds 962 948 6 1 1 1 1 1 1 1 1


Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment

Is Lilly's Dividend Safe? Is Lilly's Dividend Safe? Presentation Transcript

  • Is Lilly’s Dividend Safe?
  • Is Lilly’s dividend safe? 1. Patent expiration – Cymbalta lost patent protection in December. • Cymbalta sales totaled $5 billion in 2013. – Evista lost patent protection in March. • Evista generated $1 billion in sales during 2013. 2. Shrinking margin – Operating margin has slumped nearly 4% since 2011. 2 big and important question marks hang over Lilly’s dividend:
  • Patent expiration • Once branded drugs lose patent protection, brand sales typically fall by between 80% and 90% over time. Cymbalta and Evista’s sales are likely to continue lower throughout this year. •Cymbalta sales fell 64% a year ago to $478 million in Q1. •Evista sales fell 38% from last year to $150 million in Q1. •2014 EPS guidance exiting 2013 was for $2.77 to $2.85; down from $4.15 in 2013. – EPS Guidance was reduced to $2.72- $2.78 exiting Q1 •2014 revenue guidance exiting 2013 was for $19.2 billion to $19.8 billion, down from $23.1 billion in 2013. – Revenue guidance was adjusted to $19.4 billion to $20 billion exiting Q1. First, let’s consider Lilly’s patent calendar.
  • Shrinking margin Lilly’s operating margin has fallen from 25% to 21% since 2011 and the loss of patent protection on Cymbalta and Evista forced the company’s gross margin down 5.4% year- over-year in the first quarter. The company expects full year gross margin of 73%, down from 74% estimates exiting 2013. Lilly is restructuring to offset margin erosion with hopes of realizing $1 billion in annual savings. If so, a leaner company could help re-ignite profit once top line growth returns.
  • Reasons for dividend optimism – The company currently doesn’t boast any fast-growing new compounds. • Forteo posted the best year-over-year growth in Q1, rising 7% to $300 million. – Lilly needs a blockbuster win from its R&D pipeline. • Dulaglutide is a GLP-1 diabetes therapy under FDA review for approval. – In trials once-weekly dulaglutide was as effective as Novo’s once-daily blockbuster drug Victoza. – If approved dulaglutide will also compete against AstraZeneca’s Bydureon and Byetta. • Empagliflozin is a SGLT-2 diabetes therapy recently denied by the FDA for approval. – The denial was based on manufacturing concerns at partner Boehringer’s European plant, not empagliflozin’s efficacy or safety. – Concerns have since been resolved, allowing for a resubmission for approval. If approved, it will compete against Johnson’s Invokana and Astra’s Farxiga. • Cyramza won FDA approval in post-chemotherapy gastric cancer in April. – 1 million new cases diagnosed annually; 3rd leading cause of cancer death. – Potential as a lung cancer treatment. Lilly is developing new products that could offset patent risk.
  • Cash dividend payout Lilly’s cash dividend payout ratio, which measures how much of a company’s operating cash minus capital expenses and preferred dividends is being spent to pay common dividends, is 47%. That’s lower than Novo-Nordisk, which competes against Lilly with products including the insulin Novolog, and AstraZeneca, which markets various diabetes drugs including the DPP-4 drug Onglyza. Theoretically, Lilly’s lower ratio puts it in a better position to eventually boost its dividends, but only once sales stabilize.
  • Current yield Lilly’s dividend yield is 3.3%, which trails AstraZeneca’s 3.79% rate, but is higher than Novo’s 1.33% yield. While that yield is intriguing, patent risks and pipeline uncertainty suggest dividend investors approach Lilly cautiously.
  • . The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That’s beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor’s portfolio. To see our free report on these stocks, just click here now.